



Observational Cohort Study of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt (TIPS)

Michaela Routhu,* Vaclav Safka,† Sunil Kumar Routhu,‡ Tomas Fejfar,§
Vaclav Jirkovsky,§ Antonin Krajina,|| Eva Cermakova,¶ Petr Hulek,§ Ladislav Hosak**,††

* School of Psychiatry, Health Education Wessex, United Kingdom.

† Department of Physiology, Faculty of Medicine in Hradec Kralove, Charles University in Prague, Czech Republic.

‡ School of Psychiatry, Health Education West Midlands, United Kingdom.

§ Department of Internal Medicine, University Hospital in Hradec Kralove, Czech Republic.

|| Department of Radiology, University Hospital in Hradec Kralove, Czech Republic.

¶ Computer Technology Center, Faculty of Medicine in Hradec Kralove, Charles University in Prague, Czech Republic.

** Department of Psychiatry, University Hospital in Hradec Kralove, Czech Republic.

†† Department of Psychiatry, Faculty of Medicine in Hradec Kralove, Charles University in Prague, Czech Republic.

ABSTRACT

Introduction and aim. Hepatic encephalopathy (HE) is a common complication of transjugular intrahepatic portosystemic shunting (TIPS). It is associated with a reduced quality of life and poor prognosis. The aim of this study was to compare two groups of patients who did and did not develop overt HE after TIPS. We looked for differences between these groups before TIPS. **Material and methods.** A study of 895 patients was conducted based on a retrospective analysis of clinical data. Data was analyzed using Fisher's exact test, χ^2 , Mann Whitney test, unpaired *t*-test and logistic regression. After the initial analyses, we have looked at a regression models for the factors associated with development of HE after TIPS. **Results.** 257 (37.9%) patients developed HE after TIPS. Patients' age, pre-TIPS portal venous pressure, serum creatinine, aspartate transaminase, albumin, presence of diabetes mellitus and etiology of portal hypertension were statistically significantly associated with the occurrence of HE after TIPS ($p < 0.01$). However, only the age, pre-TIPS portal venous pressure, serum creatinine, presence of diabetes mellitus and etiology of portal hypertension contributed to the regression model. Patients age, serum creatinine, presence of diabetes mellitus and portal vein pressure formed the model describing development of HE after TIPS for a subgroup of patients with refractory ascites. **Conclusion.** We have identified, using a substantial sample, several factors associated with the development of HE after TIPS. This could be helpful in further research.

Key words. Creatinine. Diabetes mellitus. Ascites. Portal vein pressure. Age.

INTRODUCTION

Transjugular intrahepatic portosystemic shunt (TIPS) has been widely used in the treatment of patients with portal hypertension. One of the common complications associated with TIPS is the development of hepatic encephalopathy (HE).

HE is defined by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases as a brain dysfunction caused by liver insufficiency and/or portosystemic shunting; it manifests as a wide spectrum of neurological or psychiatric abnormalities ranging from subclinical alterations to coma.¹

Based on the neurological and psychiatric abnormalities HE is graded from Unimpaired to Grade IV. Grades II-IV are categorised as 'overt' grades with clinical findings ranging from lethargy, apathy, disorientation for time, obvious personality change, inappropriate behaviour, dyspraxia and asterixis in Grade II to coma in Grade IV.¹

Studies have shown that about 30% of patients developed new or worsened HE after TIPS.^{2,3} The pooled estimate of new or worsening HE was 32% in the study of Russo, *et al.*⁴ Post-TIPS, HE reduces quality of life.⁵ Furthermore, 10% of post-TIPS HE cases require a liver transplant or die.² The more severe the HE the smaller the chances of survival.⁶

Several studies have been conducted to investigate predictors for the development and progress of HE in post-TIPS patients. Several factors, such as: higher patient's age,^{3,7-12} female sex,¹³ comorbid diabetes mellitus (DM),⁷ etiology of liver cirrhosis,^{7,8,13} non-alcoholic causes of portal hypertension,^{13,14} ascites as the indication for TIPS,¹¹ hypoalbuminaemia,^{13,15} high serum creatinine,⁸ hepatofugal pre-TIPS portal flow,^{16,17} high Child-Pugh score,^{8,18} high reduction of the portosystemic pressure gradient,¹⁹ reduced liver function,²⁰ and placing an uncovered stent²¹ have all been variably associated with the post-TIPS HE. However, some of these possible predictors such as: age, sex, stage of cirrhosis, Child-Pugh score, indication for TIPS, hepatic arterial blood flow changes after TIPS or type of stent have been challenged by other studies.^{15,17,22-27} Some of the studies had sampled less than 100 subjects.^{8-10,16,19-21}

The primary aim was to study the association of pre-existing patient factors with the development of post-TIPS HE.

The secondary aim was to consider the subgroup of patients with refractory ascites, where knowing which patients are at high risk of developing HE after TIPS, could perhaps in some cases help to consider the alternative of repeated paracentesis. Repeated paracentesis is a commonly used alternative to TIPS for refractory ascites with lesser risk of HE.²⁸ There has been a call for the predictors of post-TIPS HE to be found, to rationalize clinical decision making in this group of patients.²⁹

MATERIAL AND METHODS

Study design

This is a single centre, retrospective observational cohort study based on the analysis of clinical data collected prospectively in a departmental database. The research was submitted to the Research and Ethics Committee of the University Hospital who concluded that the project did not require ethical approval as it is a retrospective, anonymous survey.

Study sample

Patients, who underwent TIPS between September 1992 and August 2011, were included in the study. We excluded patients under 18 years of age and patients with an unsuccessful TIPS insertion. We also excluded patients with pre-TIPS HE.

Procedure

At the Internal Medicine Department, TIPS was first introduced in 1992. As this was a new procedure then,

clinical data was carefully sampled to ensure the safety of patients was maintained at a high standard. Before the TIPS procedure was performed, the presence of physical co-morbidities, physical examination and blood test results were documented (Table 1 and Table 2). A standard TIPS procedure was performed.^{30,31}

Uncovered stents were used until 2000, as stentgrafts (covered stents) were not available. Mix of covered and uncovered stents has been used since 2000. Due to the price of the covered stents, covered stents are being given to patients with longer life expectancy and if the patients are due to have a liver transplantation (temporary TIPS).

Shunt patency was assessed using Doppler ultrasound one month after TIPS and then three monthly.³² TIPS revision was indicated in the case of significant stenosis of the shunt. Balloon dilatation or insertion of another stent was performed if needed. All patients in the study had patent shunt during the follow up period.

Assessment of HE

Our information about the development of overt post-TIPS HE was based on close follow up of patients after the TIPS procedure. Interview and a simple task such as asking the patient to provide a signature were used. Collateral information from family gave significant insight into the grade of HE. As this was a clinical setting, no battery of psychometric tests was used. No psychometric tests are needed for diagnosis of overt HE.¹

Follow up

Patients had a daily review for 1 week during their inpatient stay after the TIPS procedure and outpatient follow up with a consultant hepatologist at: 1 month, 3 months and 6 months after the TIPS procedure. Further follow up appointments at 3-6 months were made thereafter. This was based on previous reports that most of the patients develop HE during the first 3 months after TIPS.² Families and patients were educated to contact the hepatology service if any signs of HE appeared, and the hepatology nurse maintained frequent contact with the patients and their families. Additional urgent appointments with a consultant were provided if any complications, including HE, were suspected, and this was recorded accordingly.

Statistical methods

Data was analyzed using the statistical program SPSS version 19.0³³ and NCSS 9.³⁴ Statistical significance was taken as $p < 0.01$ due to higher number of tested variables. We used Fisher exact test and χ^2 test for categorical variables, and the Mann Whitney test for quantitative data, to

identify factors associated with development of HE. Statistically significant variables were used in the logistic binary regression analysis. For positively skewed values, the natural logarithm was used to improve the model.

We then used unpaired t-test to look for differences between group of patients with diabetes on oral versus insulin treatment, and for differences between group who underwent urgent TIPS.

We then performed a separate analysis for the subgroup of patients with refractory ascites to identify the factors

statistically associated with development of hepatic encephalopathy for this subgroup (Table 1 and Table 2).

RESULTS

After applying the exclusion criteria (Figure 1), we obtained a final sample of 678 subjects. Most patients in the cohort were male (64%) with alcoholic liver disease (55%) and variceal bleeding (54%). There were 183, 320 and 166 patients with the Child Pugh score A, B and C, respectively.

Table 1. Descriptive Statistics of quantitative data.

Variable	Minimum	Maximum	Mean	Standard Deviation	Units	P Value*	P Value Refractory Ascites*
Age at TIPS	18.3	83.1	54.5	11.6	years	<0.001	< 0.001
Pre-TIPS Hepatic Venous Pressure	0	34	9.7	4.1	mmHg	0.081	0.491
Pre-TIPS Portal Venous pressure	5	54	30.6	6.3	mmHg	0.002	0.019
Pre-TIPS Portal Pressure Gradient	6	41	20.6	5.7	mmHg	0.049	0.046
Post-TIPS Hepatic Venous Pressure	0	29	13.2	4.4	mmHg	0.010	0.049
Post-TIPS Portal Venous pressure	5	41	21.4	5.4	mmHg	0.244	0.376
Post-TIPS Portal Pressure Gradient	1	24	8.4	3.9	mmHg	0.613	0.777
Diameter of The Stent	6	14	10.8	1.2	mm	0.547	0.837
Shunt Length	20	160	81.1	14.0	mm	0.879	0.145
Decompression of Shunt	-5	27	9.3	4.3	mmHg	0.138	0.038
Systolic Blood Pressure	50	190	124.3	19.9	mmHg	0.861	0.548
Diastolic Blood Pressure	30	120	73.8	12.1	mmHg	0.344	0.471
Heart Rate	48	142	83.5	15.7	/min.	0.037	0.031
Sodium	104	152	134.3	6.1	Mmol/L	0.395	0.473
Serum Creatinine	48	740	100.6	71.9	Micromol/L	< 0.001	0.003
Serum Bilirubin	3	654	48.0	62.0	Micromol/L	0.590	0.579
Conjugated Bilirubin	0	438	34.6	53.8	Micromol/L	0.956	0.566
Alanine Aminotransferase	4.7	564.7	67.4	47.0	U/L	0.010	0.185
Aspartate Transaminase	5.9	588.2	70.6	61.65	U/L	0.008	0.262
Gamma-Glutamyltransferase	12	929.8	155.9	148.9	U/L	0.047	0.109
Alkaline Phosphatase	29.4	1588.2	158.8	138.8	U/L	0.217	0.440
Total Protein	39.9	97.5	65.9	12.1	g/L	0.551	0.807
Albumin	14.6	51.9	30.8	6.5	g/L	0.006	0.080
International Normalized Ratio	0.3	11	1.5	0.6	N/A	0.998	0.870
Total Cholesterol	0.7	8.1	3.3	1.2	Mmol/L	0.486	0.962
Ammonia	7	309	62.5	40.6	Micromol/L	0.491	0.599
Pre TIPS Child-Pugh Points	5	14	8.3	2.2	N/A	0.020	0.479

* P-value refers to the differences between patients with and without HE using the Mann-Whitney test. Significant differences ($P < 0.01$) were marked in bold. P values are uncorrected for multiple comparison.

Table 2. Variables before TIPS. Categorical data.

Variable	P Value*	P Value Refractory Ascites*
Diabetes mellitus	< 0.001	0.011
Sex	0.472	0.886
Etiology of portal hypertension	< 0.001	0.004
Indication of TIPS	0.381	N/A
Urgency of TIPS	0.688	0.520
Type of the Stent (Covered vs. Non-covered)	0.302	0.217
Two shunts used	0.736	1.000
Pre TIPS Child-Pugh Class	0.136	0.737

* P-value refers to the differences between patients with and without HE using the χ^2 and Fisher's exact test. Significant differences ($P < 0.01$) were marked in bold. P values are uncorrected for multiple comparison.




Figure 1. Excluded patients.

One hundred ninety-two patients had DM (79 on insulin). In 57 cases portal vein thrombosis was present prior to the TIPS procedure. For the purpose of statistical analysis, we have grouped the etiology of portal hypertension into following groups: viral hepatitis, autoimmune hepatitis, alcoholic, cholestatic, vascular/non-cirrhotic, NAFLD/cryptogenic, rare/congenital, multiple diagnoses/combinations. The descriptive statistics of the sample are summarized in Table 1, Figures 2 and 3.

The team used a covered stent in 234 (34.5%) cases. One hundred twenty-seven (18.7%) of the TIPS insertions were urgent. After TIPS, 257 (37.9%) patients developed HE. Fourteen patients required reduction of the shunt because of the severity of HE. Fifty-three of the patients who had undergone TIPS were later listed for orthotopic liver transplantation. The mean length of follow up after TIPS was 35 months. The mortality in 4 weeks was 11.5%; the mortality in one year was 37%.

We found 7 statistically significant variables associated with development of HE ($p < 0.01$) (Tables 1 and 2). High age, pre-TIPS portal venous pressure, serum creatinine, aspartate transaminase, low albumin, presence of DM and etiology of portal hypertension were all associated with the development of HE after TIPS. The regression model describing the development of HE after TIPS is summarized in Tables 3 and 4. In terms of the etiology of portal hypertension, 95% of vascular/non-cirrhotic patients were HE free after TIPS. On the other hand, 64% of patients with viral hepatitis and 65% of patients with alcoholic liver disease did develop new HE after TIPS.




Figure 2. Etiology of portal hypertension.




Figure 3. Indication for transjugular intrahepatic portosystemic shunt.

For patients with refractory ascites, the main variables associated with development of HE after TIPS were age and serum creatinine. The regression model describing the development of HE after TIPS in this subgroup is summarized in Tables 3 and 4. The etiology of portal hypertension was statistically significant for the subgroup however due to smaller frequencies it did not contribute to the regression model. 100% of the of vascular/non-cirrhotic patients were HE free after TIPS and 65% of patients with viral hepatitis developed HE after TIPS. The alcoholic cause to portal hypertension was not significantly associated with HE after TIPS. Pre-TIPS portal venous pressure and DM were bordering on being significant and did contribute to the regression model.

Table 3. Results of logistic regression.

Model for any HE (Percent correctly classified = 68.0%)			
	No HE	HE	Total
No HE	261	122	383
HE	75	158	233
Total	336	280	616

Model for Refractory Ascites (Percent correctly classified = 62.5%)			
	No HE	HE	Total
No HE	72	44	116
HE	28	48	76
Total	100	92	192

The urgency of TIPS was not shown to be statistically significant. From our observations we hypothesized that this might be due to patients undergoing urgent TIPS being younger than those undergoing non-urgent TIPS. This difference was confirmed ($p = 0.018$, unpaired t-test).

DM was a strong predictor of HE. Interestingly, the patients treated with insulin did not statistically differ from the group of patients on diet or oral anti-diabetics ($p > 0.8$, unpaired t-test).

DISCUSSION

This is a study of the association of preexisting variables on the development of HE. We confirmed the importance of age, pre-TIPS portal venous pressure, serum creatinine, DM and etiology of portal hypertension in the incidence of post-TIPS HE.

The regression models used were able to successfully sort around 60% cases. Therefore the models are suitable for description of the factors associated with development of HE and not for its prediction.

The association between hepatic encephalopathy and albumin levels, creatinine and aspartate transaminase is probably due to severity of liver damage.^{35,36} The pre-TIPS portal venous pressure, likely an indicator of severity of portal hypertension,³⁷ was associated with hepatic encephalopathy after TIPS.

It was reported that older people are more likely to develop hepatic encephalopathy, possibly due to age-related vulnerability of the brain.³⁸ This is in concordance with our findings that age is a very important predictor of HE after TIPS.

Table 4. Results of Odds Ratio.

	Odds Ratio	Confidence Interval
Model for any HE		
Age at TIPS	1.047	1.026 - 1.068
Creatinine	1.005	1.002 - 1.009
Cholestatic etiology of portal hypertension	0.455	0.129 - 1.604
Multiple causes for portal hypertension	0.330	0.092 - 1.183
Idiopathic liver disease as etiology of portal hypertension	0.554	0.189 - 1.626
Alcoholic liver cirrhosis as etiology of portal hypertension	0.462	0.171 - 1.250
Rare / Congenital etiology of portal hypertension	0.517	0.113 - 2.372
Vascular / Non-cirrhotic etiology of portal hypertension	0.074	0.013 - 0.437
Viral hepatitis as etiology of portal hypertension	1.220	0.380 - 3.919
Patients on oral treatment for diabetes mellitus	1.487	0.923 - 2.397
Patients on insulin treatment for diabetes mellitus	1.863	1.070 - 3.244
Pre-TIPS portal venous pressure	1.048	1.015 - 1.081
Model for refractory ascites		
Age at TIPS	1.057	1.021 - 1.094
Creatinine	1.004	1.000 - 1.009
Patients on oral treatment for diabetes mellitus	1.997	0.831 - 4.802
Patients on insulin treatment for diabetes mellitus	0.691	0.280 - 1.706
Pre-TIPS portal venous pressure	1.062	1.002 - 1.125

DM is associated with reduced psychomotor functions, a lower attention span and impaired memory.³⁹ The pre-existing vulnerability of the brain could explain development of hepatic encephalopathy after TIPS for both older people and individuals with DM. TIPS affecting the homeostasis could trigger the HE if there was a pre-existing condition.

Due to the benefit of having large data, we were able to confirm that previously reported sex differences in development of HE in small samples³ were more likely random findings.

There was no significant difference between covered and non-covered stents in terms of association with development of HE after TIPS in this study.

The percentage of alcohol-related portal hypertension cases in our sample was consistent with world literature.^{40,41}

The etiology of liver cirrhosis complicated by portal hypertension is sometimes difficult to establish exactly in each individual. The self-reported alcohol consumption in the subgroup of patients who drink alcohol but also meet the criteria for NAFLD presents a diagnostic challenge. People in general have a tendency to report lower alcohol consumption than is their real consumption.⁴²

NAFLD is one of the newer diagnoses.⁴³ Therefore, some patients who might have been in the past given diagnosis of idiopathic cirrhosis might be nowadays diagnosed with NAFLD. This is the case especially for number of patients suffering from diabetes mellitus type II.⁴⁴

It might be expected that the TIPS procedures performed urgently, and often associated with disrupted homeostasis, would be associated with HE. However, the

fact that these patients were younger than those undergoing non-urgent TIPS could explain the result (as above).

Majority of the TIPS were done for variceal bleeding. However, there were only 18.7% urgent TIPS in the whole sample. This is because some of the TIPS were done preventively for patients with a history of multiple variceal bleedings. Nowadays, due to the improvements in endoscopic interventions, the number of patients indicated to preventive TIPS is decreasing.⁴⁵

Ascites as the indication for TIPS was not associated with development of HE in our sample, unlike in other studies.¹¹ As patients suffering with ascites usually have, as a group, bigger liver damage, one would expect that these patients would be at higher risk of developing HE after TIPS. The patients with portal hypertension from vascular reasons (Budd-Chiari syndrome) might still have a good liver function and hence lower risk of HE. We presume that the reason why indication for TIPS was not statistically significantly associated with the development of HE might be because some very unwell patients were included in the study overall.

In our sample, 65% of patients with alcoholic liver disease developed new HE after TIPS. This is in contrast with previous findings where non-alcoholic causes of portal hypertension were associated with HE after TIPS.^{13,14} We believe, that the likelihood of developing HE after TIPS depends on whether the person stops drinking alcohol after TIPS or not. If the person continues drinking, their cirrhosis is likely to get worse and their brain is likely to get more damaged. Around the time of TIPS procedure, the patients are offered interventions for alcohol problems when in hospital, and patients are

more motivated to stop drinking. The key issue is that we are missing data about who abstained from alcohol after TIPS. This can cause a bias in our study as well as in the other mentioned studies.^{13,14} It is therefore difficult to conclude whether the alcoholic or non-alcoholic cause predisposed patients to developing HE after TIPS. 64% of patients with viral hepatitis disease did develop new HE after TIPS. The viral hepatitis more often progressed and led to worsening of clinical picture and development of HE.

In terms of the study limitations, the study was retrospective, which brings limitations such as inability to control for confounding factors, some missing data and lost to follow up. The TIPS is highly specialized procedure and therefore the centre covered a large geographic area making follow up attendance difficult for some patients from distant cities, leading to slightly higher lost to follow up.

As TIPS was used since 1992, its target patient group was not well established in the beginnings. This has led to some outliers in the sample, such as the patient with bilirubin of 654. Gradually the most unwell patients from the Child-Pugh grade C group started being excluded from TIPS referrals. Nowadays, TIPS is not indicated for patients with Child Pugh score over 12.

TIPS procedure is completed for all patients in a standard way. Very most of the patients had 10mm stent inserted. However, the impact on the Portal Pressure Gradient is individual. The lower mean of Portal Pressure Gradient might be also caused by some outliers in the minimum range of the measurements.

High reduction of the portosystemic pressure gradient was reported to lead to development of HE.¹⁹ The higher the reduction of the portosystemic pressure gradient, the lower the risk of bleeding⁴⁶ and the better are the chances that ascites will reduce. Clinicians are aware that the higher the reduction of the portosystemic pressure gradient, the higher the chances of developing HE due to reduced blood flow through liver.

The study presents real world data. This brings its own advantages and limitations. The diagnosis of hepatic encephalopathy was made by hepatologists. In our opinion, this is not necessarily a limitation of the study. In practice, the diagnosis of overt HE is frequently made by hepatologists. HE prophylaxis was not recorded for statistical analysis due to the variability in individual prescribing based on clinical judgment. The results therefore represent the risks for an uncontrolled population of patients undergoing TIPS, rather than for a treatment naive population.

It was not the aim of the study to follow up of the development of HE in detail. It would be beneficial to see, in future prospective studies, how the symptoms of HE develop over time. Further studies could also focus on comparing the blood results at the time of any episodes of HE.

The study focused on differences in baseline characteristics of patients who did, and who did not, develop HE after TIPS. Since the study focused on correlation, it cannot draw conclusions about a causality between the baseline characteristics and development of HE after TIPS. It merely describes that people with a certain baseline characteristics are more likely to develop HE after TIPS, whether those characteristics are directly involved in the development of the HE or not.

We hope this large real-world-data study will help to conduct future studies focusing on specific predictors of HE after TIPS.

ACKNOWLEDGMENTS

The authors would like to thank Mr Christopher West, Honorary Senior Fellow of the Department of Public Health and Policy, University of Liverpool, for the valuable statistical support.

ABBREVIATIONS

- **DM:** diabetes mellitus.
- **HE:** hepatic encephalopathy.
- **TIPS:** transjugular intrahepatic portosystemic shunting.

FINANCIAL SUPPORT

The study was supported by the research grant IGA NS/10363-3 (by the Ministry of Health).

REFERENCES

1. American Association for the Study of Liver Diseases, European Association for the Study of the Liver. Hepatic Encephalopathy in Chronic Liver Disease: 2014 Practice Guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases. *J Hepatol* 2014; 61: 642-59.
2. Masson S, Mardini HA, Rose JD, Record CO. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt insertion: a decade of experience. *QJM* 2008; 101: 493-501.
3. Zuckerman DA, Darcy MD, Bocchini TP, Hildebolt CF. Encephalopathy after transjugular intrahepatic portosystemic shunting: analysis of incidence and potential risk factors. *AJR Am J Roentgenol* 1997; 169: 1727-31.
4. Russo MW, Sood A, Jacobson IM, Brown RS. Transjugular intrahepatic portosystemic shunt for refractory ascites: an analysis of the literature on efficacy, morbidity, and mortality. *Am J Gastroenterol* 2003; 98: 2521-7.
5. Campbell MS, Brensinger CM, Sanyal AJ, Gennings C, Wong F, Kowdley KV, Mccashland T, et al. Quality of life in refractory ascites: transjugular intrahepatic portal-systemic shunting versus medical therapy. *Hepatology* 2005; 42: 635-40.
6. Stewart CA, Malinchoc M, Kim WR, Kamath PS. Hepatic encephalopathy as a predictor of survival in patients with end-stage liver disease. *Liver Transpl* 2007; 13: 1366-71.

7. Stefánková J, Hulek P, Babu A, Cermáková E, Safka V, Stefanek J, Fejfar T, et al. Hepatic encephalopathy due to TIPS-retrospective study. *Hepatogastroenterology* 2007; 54: 480-4.
8. ter Borg PC, Hollemans M, Van Buuren HR, Vleggaar FP, Groeneweg M, Hop WC, Laméris JS. Transjugular Intrahepatic Portosystemic Shunts: Long-term Patency and Clinical Results in a Patient Cohort Observed for 3–9 Years. *Radiology* 2004; 231: 537-45.
9. Riggio O, Merli M, Pedretti G, Servi R, Meddi P, Lionetti R, Rossi P, et al. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Incidence and risk factors. *Dig Dis Sci* 1996; 41: 578-84.
10. Sanyal AJ, Freedman AM, Shiffman ML, Purdum PP, Luketic VA, Cheatham AK. Portosystemic encephalopathy after transjugular intrahepatic portosystemic shunt: results of a prospective controlled study. *Hepatology* 1994; 20: 46-55.
11. Mamiya Y, Kanazawa H, Kimura Y, Narahara Y, Yamate Y, Nakatsuka K, Sakamoto C. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. *Hepatol Res* 2004; 30: 162-8.
12. Hassoun Z, Deschênes M, Lafortune M, Dufresne MP, Perreault P, Lepanto L, Gianfelice D, et al. Relationship between pre-TIPS liver perfusion by the portal vein and the incidence of post-TIPS chronic hepatic encephalopathy. *Am J Gastroenterol* 2001; 96: 1205-9.
13. Somberg KA, Riegler JL, Laberge JM, Doherty-Simor MM, Bachetti P, Roberts JP, Lake JR. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunts: incidence and risk factors. *Am J Gastroenterol* 1995; 90: 549-55.
14. Rössle M, Deibert P, Haag K, Ochs A, Olschewski M, Siegerstetter V, Hauenstein KH, et al. Randomised trial of transjugular-intrahepatic-portosystemic shunt versus endoscopy plus propranolol for prevention of variceal rebleeding. *Lancet* 1997; 349: 1043-9.
15. Bahn E, Nolte W, Kurth C, Ramadori G, Rütger E, Wiltfang J. Quantification of the electroencephalographic theta/alpha ratio for the assessment of portal-systemic encephalopathy following implantation of transjugular intrahepatic portosystemic stent shunt (TIPSS). *Metab Brain Dis* 2002; 17: 19-28.
16. François E, García-Pagán JC, Bru C, Feu F, Gilabert R, Escorsell A, Bosch J, et al. [Effects of percutaneous intrahepatic portosystemic shunt on splanchnic and systemic hemodynamics in patients with portal hypertension]. *Gastroenterol Hepatol* 1997; 20: 1-4.
17. Deng D, Liao MS, Qin JP, Li XA. Relationship between pre-TIPS hepatic hemodynamics and postoperative incidence of hepatic encephalopathy. *Hepatobiliary Pancreat Dis Int* 2006; 5: 232-6.
18. Bai M, Han GH, Yuan SS, Yin ZX, He CY, Wang JH, Qi XS, et al. [Early hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: the risk factors and long-time survival]. *Zhonghua Gan Zang Bing Za Zhi* 2011; 19: 498-501.
19. Nägele T, Seeger U, Pereira P, Seitz D, Klose U, Kaiser S, Eisold M, et al. [MR proton spectroscopy to monitor the concentration changes in cerebral metabolites following a TIPS placement]. *Rofo* 1999; 170: 298-303.
20. Nolte W, Wiltfang J, Schindler C, Münke H, Unterberg K, Zumhasch U, Figulla HR, et al. Portosystemic hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with cirrhosis: clinical, laboratory, psychometric, and electroencephalographic investigations. *Hepatology* 1998; 28: 1215-25.
21. Bureau C, Pagan JC, Layrargues GP, Metivier S, Bellot P, Perreault P, Otal P, et al. Patency of stents covered with polytetrafluoroethylene in patients treated by transjugular intrahepatic portosystemic shunts: long-term results of a randomized multicentre study. *Liver Int* 2007; 27: 742-7.
22. Stefánková J, Fejfar T, Safka V, Hulek P, Krajina A, Fendrichová M. [Hepatic encephalopathy after TIPS-retrospective study]. *Vnitř Lek* 2002; 48: 390-5.
23. Angeloni S, Merli M, Salvatori FM, De Santis A, Fanelli F, Pepino D, Attili AF, et al. Polytetrafluoroethylene-covered stent grafts for TIPS procedure: 1-year patency and clinical results. *Am J Gastroenterol* 2004; 99: 280-5.
24. Thuluvath PJ, Bal JS, Mitchell S, Lund G, Venbrux A. TIPS for management of refractory ascites: response and survival are both unpredictable. *Dig Dis Sci* 2003; 48: 542-50.
25. Amarapurkar DN, Punamiya S, Patel ND. An experience with covered transjugular intrahepatic portosystemic shunt for refractory ascites from western India. *Ann Hepatol* 2006; 5: 103-8.
26. Patel NH, Sasadeusz KJ, Seshadri R, Chalasani N, Shah H, Johnson MS, Namyslawski J, et al. Increase in hepatic arterial blood flow after transjugular intrahepatic portosystemic shunt creation and its potential predictive value of postprocedural encephalopathy and mortality. *J Vasc Interv Radiol* 2001; 12: 1279-84.
27. Pomier-Layrargues G, Villeneuve JP, Deschênes M, Bui B, Perreault P, Fenyves D, Willems B, et al. Transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic variceal ligation in the prevention of variceal rebleeding in patients with cirrhosis: a randomised trial. *Gut* 2001; 48: 390-6.
28. Ginès P, Arroyo V. Paracentesis in the management of cirrhotic ascites. *J Hepatol* 1993; 17(Suppl. 2): 14-8.
29. D'Amico G, Luca A, Morabito A, Miraglia R, D'Amico M. Uncovered transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis. *Gastroenterology* 2005; 129: 1282-93.
30. Gordon JD, Colapinto RF, Abecassis M, Makowka L, Langer B, Blendis LM, Taylor B, et al. Transjugular intrahepatic portosystemic shunt: a nonoperative approach to life-threatening variceal bleeding. *Can J Surg* 1987; 30: 45-9.
31. Krajina A, Hulek P, Eliás P, Michl A, Heger L, Volfová M, Niangová I, et al. [Transjugular intrahepatic portosystemic shunt]. *Cor Vasa* 1993; 35: 157-61.
32. Zizka J, Eliás P, Krajina A, Michl A, Lojík M, Ryska P, Masková J, et al. Value of Doppler Sonography in Revealing Transjugular Intrahepatic Portosystemic Shunt Malfunction. *AJR Am J Roentgenol* 2000; 175(1): 141-8.
33. IBM Corp.: Released 2010. IBM SPSS Statistics for Windows, Version 19.0. Armonk, NY: IBM Corp.
34. Hintze J: NCSS 9. NCSS, LLC. Kaysville, Utah, USA. www.NCSS.com.
35. Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, Kremers W, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. *Gastroenterology* 2003; 124: 91-6.
36. Child CG, Turcotte JG. Surgery and portal hypertension. In: Child CG (eds.). *The liver and portal hypertension*. Philadelphia: Saunders; 1964, p. 50-64.
37. Kumar A, Sharma P, Sarin SK. Hepatic venous pressure gradient measurement: time to learn! *Indian J Gastroenterol* 2008; 27: 74-80.
38. Quero JC, Hartmann IJ, Meulstee J, Hop WC, Schalm SW. The diagnosis of subclinical hepatic encephalopathy in patients with cirrhosis using neuropsychological tests and automated electroencephalogram analysis. *Hepatology* 1996; 24: 556-60.
39. Awad N, Gagnon M, Messier C. The Relationship between Impaired Glucose Tolerance, Type 2 Diabetes, and Cognitive Function. *J Clin Exp Neuropsychol* 2004; 26: 1044-80.

40. Friedman S, Schiano T. Cirrhosis and its sequelae. In: Goldman L, Ausiello D (eds.). Cecil Textbook of Medicine. 22nd ed. Philadelphia: Saunders; 2004, p. 936-44.
41. Crawford JM. Liver and biliary tract. In: Kumar V, Abbas AK, Fausto N (eds.). Robbins and Cotran Pathologic Basis of Disease. 7th ed. Philadelphia: Elsevier Saunders; 2005, p. 877-938.
42. Stockwell T, Zhao J, Greenfield T, Li J, Livingston M, Meng Y. Estimating under- and over-reporting of drinking in national surveys of alcohol consumption: Identification of consistent biases across four English-speaking countries. *Addiction* 2016; 7: [Epub ahead of print].
43. Rinella ME, Loomba R, Caldwell SH, Kowdley K, Charlton M, Tetri B, Harrison SA. Controversies in the Diagnosis and Management of NAFLD and NASH. *Gastroenterol Hepatol* (N Y) 2014; 10(4): 219-27.
44. Leite NC, Villela-Nogueira CA, Cardoso CRL, Salles GF. Non-alcoholic fatty liver disease and diabetes: From physiopathological interplay to diagnosis and treatment. *World J Gastroenterol* 2014; 20(26): 8377-92.
45. Pomier-Layrargues G, Villeneuve J, Deschenes M, Bui B, Perreault P, Fenyves D, Willems B, et al. Transjugular intra-hepatic portosystemic shunt (TIPS) versus endoscopic variceal ligation in the prevention of variceal rebleeding in patients with cirrhosis: a randomised trial. *Gut* 2001; 48(3): 390-6.
46. Biecker E, Roth F, Heller J, Schild HH, Sauerbruch T, Schepke M. Prognostic role of the initial portal pressure gradient reduction after TIPS in patients with cirrhosis. *Eur J Gastroenterol Hepatol* 2007; 19(10): 846-52.

Correspondence and reprint request:

Dr. Michaela Routhu, MRCPsych
Ravenswood House Hospital,
Mayles Lane, Knowle, Fareham, United Kingdom, PO17 5NA.
Tel.: 01329 836000. Fax: 01329 836196
E-mail: michaela.routhu@nhs.net